Study at a glance
What is the difference between vitamin D status and vitamin D effect?
Status describes vitamin D supply, usually assessed through a blood test. Effect describes what the body does with that supply after transport, processing and responses inside cells.
Why can similar vitamin D blood levels produce different responses?
People and tissues can differ in how vitamin D is carried, activated, broken down and recognised by cells. The blood result captures one part of that system.
Does a higher blood level after supplements prove better health?
It proves that the measured vitamin D status changed. Whether symptoms, bone health or another outcome improves is a separate question that needs appropriate evidence.
Are vitamin D blood tests still useful?
Yes. The usual test remains an established measure of vitamin D status. Its limits define what can be inferred from it; they do not make the measurement meaningless.
Read the full article below ↓A vitamin D blood level is scientifically useful because it measures an important part of vitamin D physiology, but the meaning of that measurement depends on where it sits in the biological pathway. Routine assessment principally uses circulating 25-hydroxyvitamin D [25(OH)D] as a biomarker of vitamin D status. That concentration reflects the circulating substrate pool generated from skin synthesis, food and supplements. Biological effect occurs farther downstream, after transport, tissue delivery, activation, degradation, vitamin D receptor signalling and tissue-specific cellular responses. The central synthesis across the completed evidence is therefore not that vitamin D levels are unreliable, nor that biological function can be reduced to a blood number. It is that circulating status and biological effect are connected but scientifically distinct layers of the same physiological system.
This distinction extends the parent framework in What Vitamin D Levels Represent. The completed evidence also separates two related questions. What Circulating Vitamin D Levels Measure: Biomarker Status Versus Biological Effect: Full Study asks what the circulating measurement actually represents. Why Measured Vitamin D Levels Can Diverge from Functional Biological Outcomes: Full Study asks why the biological outcome may not map to that measurement in a simple one-to-one relationship. Their combined evidence supports one integrated physiological model.
The central distinction is between measuring supply and measuring response
Serum or plasma 25(OH)D is the established principal biochemical indicator of vitamin D status. It is useful because vitamin D derived from ultraviolet-B exposure and intake is converted largely in the liver to 25(OH)D, producing a circulating pool that is substantially more abundant and persistent than the active hormone 1,25-dihydroxyvitamin D [1,25(OH)₂D]. These characteristics make 25(OH)D practical for assessing vitamin D supply over a biologically meaningful period.
That status function should not be understated. A reduced circulating 25(OH)D concentration can provide genuine information about a reduced substrate pool. A higher concentration represents a larger circulating pool. Clinical and nutritional frameworks can therefore use 25(OH)D to identify states of deficiency, insufficiency or adequacy according to the evidential purpose of the threshold being applied.
The interpretive error begins when that legitimate status function is expanded into a stronger claim: that the same concentration directly measures the amount of vitamin D action occurring throughout the body. The evidence does not support that equivalence. Vitamin D Status vs Vitamin D Effect captures the distinction directly. Status concerns the measurable state of vitamin D supply. Effect concerns what the physiological system subsequently does with that supply.
25(OH)D occupies an upstream position in a regulated physiological chain
The most coherent interpretation of the completed evidence is a pathway model. Vitamin D exposure and intake influence the amount of parent vitamin entering the system. Hepatic metabolism contributes to the circulating 25(OH)D pool. Transport proteins determine how that pool is distributed in blood. Substrate must then reach relevant tissues, where activation and degradation determine local metabolite availability. Active vitamin D can interact with the vitamin D receptor, and receptor-dependent signalling can influence gene transcription and tissue-specific physiology. Clinical or functional outcomes occur still farther downstream.
A serum 25(OH)D result therefore measures an important stage in the chain rather than the chain as a whole. This is not an unusual property of a biomarker. Biomarkers are often valuable precisely because they provide accessible information about one biologically relevant state that would otherwise be difficult to measure directly. The existence of intermediate regulation does not invalidate the biomarker; it defines its evidential boundary.
Active-hormone measurement does not collapse the pathway into one number
It may appear that measuring circulating 1,25(OH)₂D should provide a more direct measure of vitamin D effect because 1,25(OH)₂D is the active endocrine hormone. The physiology does not support that simple substitution. Renal production of circulating 1,25(OH)₂D is tightly regulated by calcium and phosphate balance, parathyroid hormone, fibroblast growth factor 23 and renal function. Its circulating concentration can therefore remain within a regulated range even when the 25(OH)D substrate pool is reduced.
This is why the distinction examined in Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D is fundamental rather than merely technical. 25(OH)D principally answers a status question; circulating 1,25(OH)₂D answers a different metabolic and endocrine question. Neither measurement alone provides a complete quantitative assay of distributed tissue-level vitamin D action.
Transport creates a distinction between the total circulating pool and its fractions
The circulating 25(OH)D pool is itself heterogeneous. Most is bound to vitamin D-binding protein, a smaller amount is albumin-bound and only a very small fraction circulates freely. Conventional total 25(OH)D measurement combines these fractions. Under many ordinary physiological conditions, total and free 25(OH)D correlate closely enough that total 25(OH)D remains a useful routine status measure.
The relationship can nevertheless change when the binding environment changes. Variation in vitamin D-binding protein or albumin can alter the proportion of the circulating pool represented by different fractions. The completed free-versus-total evidence therefore adds an important interpretive layer: total concentration is not identical to free concentration, and neither should automatically be described as a direct measurement of tissue biological effect.
Free vs Total Vitamin D Explained provides the parent physiological distinction. The deeper evidence does not establish that free 25(OH)D universally replaces total 25(OH)D. Instead, it shows why transport and binding are legitimate intermediate variables between the total circulating pool and tissue availability.
Activation creates another control point between status and effect
25(OH)D is substrate for CYP27B1-mediated production of 1,25(OH)₂D. This conversion is regulated rather than automatic. In the kidney, endocrine control adjusts active-hormone production according to mineral requirements. A given change in circulating 25(OH)D therefore does not require an identical proportional change in circulating 1,25(OH)₂D.
The distinction becomes still more important outside the kidney. Extrarenal cells can express CYP27B1 and generate active vitamin D locally. In such settings, 25(OH)D may supply an intracrine or paracrine system whose regulation differs from the renal endocrine pathway. Local active-hormone generation can therefore be biologically meaningful without being quantitatively visible in the circulating 1,25(OH)₂D concentration.
The mechanisms described in Vitamin D Activation and Vitamin D and Intracrine Activity show why circulating substrate availability and local active-hormone production should not be treated as interchangeable measurements.
Degradation means biological exposure depends on both production and removal
Vitamin D metabolism does not end with activation. CYP24A1 and associated catabolic pathways contribute to the inactivation and clearance of 25(OH)D and 1,25(OH)₂D. Vitamin D exposure at a tissue therefore reflects a balance among substrate delivery, activation and degradation.
This feedback-controlled turnover adds another reason why similar circulating 25(OH)D concentrations do not logically require identical intracellular concentrations of active hormone. The relevant biology depends partly on how rapidly metabolites are generated and partly on how rapidly they are removed. Vitamin D Clearance and Degradation develops this complementary side of the metabolic system.
Receptor competence separates ligand availability from cellular response
Even successful formation of active vitamin D does not define the final response. Canonical vitamin D action requires functional interaction with the vitamin D receptor [VDR] and the surrounding transcriptional machinery. Receptor abundance, receptor integrity, co-regulatory proteins, chromatin state and the genomic architecture of the responding cell influence the response produced by a given ligand signal.
Rare pathogenic VDR loss-of-function states provide strong causal evidence for this distinction. Severe receptor dysfunction can produce profound vitamin D-dependent physiological abnormalities even though the underlying problem cannot be reduced to a lack of circulating 25(OH)D. Rare disease should not be projected directly onto ordinary population variation, but it establishes the principle that adequate substrate and adequate receptor-mediated response are different biological requirements.
The receptor layer is explored in Vitamin D Receptors and Vitamin D Signalling Pathways. These mechanisms lie downstream from the routine status measurement and cannot be read directly from a serum 25(OH)D concentration.
Tissue specificity prevents one systemic concentration from becoming one universal effect value
Vitamin D signalling occurs across biologically different tissues. Intestinal calcium transport, mineral and bone physiology, immune-cell responses, epithelial programmes and other VDR-dependent functions do not take place in one uniform cellular environment. Tissue-specific expression of metabolic enzymes, receptor abundance and gene-regulatory machinery can therefore modify the biological consequences of vitamin D signalling.
This is one of the strongest conceptual reasons not to assign a single universal biological-effect value to one systemic serum concentration. The blood measurement is systemic. Many outcomes of interest are local, tissue-specific and endpoint-specific. A relationship between 25(OH)D and one physiological function therefore cannot automatically be transferred to every other function without evidence.
Different endpoints can legitimately have different relationships with 25(OH)D
Vitamin D research spans skeletal outcomes, mineral metabolism, biochemical markers, gene expression, immune responses, muscle outcomes and broader clinical events. These endpoints differ in causal distance from the circulating biomarker and in the number of competing determinants that influence them.
A concentration that is adequate for an established skeletal or nutritional purpose is therefore not automatically proven to maximise every proposed vitamin D-dependent function. This is the evidential boundary developed in Vitamin D Thresholds vs Targets. A deficiency threshold and a functional target answer different questions and require different supporting evidence.
A successful biomarker response is not automatically a successful clinical response
Supplementation can raise serum 25(OH)D. When it does, that is direct evidence that the intervention changed vitamin D status. Whether a clinical or functional endpoint changes is a separate causal question.
This distinction explains why an intervention can produce a clear biochemical response while producing a smaller, inconsistent or absent change in a downstream outcome. The endpoint may already be physiologically saturated, may depend only weakly on vitamin D in the studied population, may be influenced strongly by other determinants, or may require a different baseline state, duration or exposure pattern to change measurably.
The absence of a downstream effect therefore does not retroactively mean that the 25(OH)D measurement failed to represent status. It means that changing the status marker and changing the clinical endpoint are separate experimental results.
Observational associations do not erase the status-versus-effect distinction
Serum 25(OH)D is associated with numerous characteristics that can themselves influence health: season, outdoor activity, diet, supplementation, body composition, age and illness among them. A lower or higher 25(OH)D concentration can therefore correlate with an outcome for several reasons.
Some associations may reflect genuine vitamin D biology. Others may be partly explained by confounding or reverse causation. An observational relationship does not by itself establish that deliberately moving the serum concentration will reproduce the associated outcome difference. The causal meaning must be determined by the total evidence relevant to the endpoint.
Measurement uncertainty is separate from biological-response uncertainty
A further layer concerns the measurement itself. Serum 25(OH)D varies biologically with exposure, season and supplementation pattern, while laboratory methodology introduces finite analytical uncertainty. These sources of variation affect the observed biomarker before the question of downstream tissue response is even considered.
Variability in Vitamin D Measurements addresses this analytical and physiological variability. It should not be conflated with functional divergence. An assay can measure the circulating pool accurately while the circulating pool remains an incomplete proxy for downstream response. Conversely, a discrepancy may sometimes arise from measurement variability rather than unusual tissue biology.
Time adds context to a biomarker that is biologically dynamic
A serum vitamin D result is also a snapshot. Seasonal ultraviolet-B exposure, supplementation and other changes can move 25(OH)D over time. A concentration measured at one point therefore does not automatically represent a person’s long-term average status.
This temporal dimension matters when relating a single blood result to a physiological outcome that develops over weeks, months or years. The relevant exposure for the outcome may not be fully represented by one measurement. Short-Term vs Long-Term Vitamin D Status develops the distinction between a transient measurement and a longer biological pattern.
Population thresholds remain useful despite individual variation
The existence of regulated intermediate steps does not mean population-level interpretation should be abandoned. Population evidence can identify concentrations associated with increased risk of deficiency-related physiology or with adequacy for defined endpoints. Those thresholds have legitimate scientific and clinical functions.
What they do not necessarily provide is a deterministic map from one concentration to one biological state in every individual. Continuous physiology, analytical uncertainty and individual variation mean that thresholds are boundaries used for defined purposes rather than universal molecular switches.
Individual variability should not be converted into unlimited personalisation
Transport, metabolism, receptor biology and tissue context create real mechanisms through which response can vary. That evidence should not be stretched into the claim that every person has a unique unknowable vitamin D target. Demonstrating that a mechanism can produce variability is different from proving that routinely measuring that mechanism improves individual prediction.
Common genetic variants, binding-protein differences and other proposed modifiers require evidence showing the size, consistency and clinical importance of their effects before they can justify different targets or treatment rules. Rare genetic disorders can reveal causal physiology without defining ordinary population requirements.
Biomarker limitations do not imply that higher concentrations are inherently better
One particularly important inference must be rejected. If serum 25(OH)D is not a complete direct measurement of tissue effect, it does not follow that increasing 25(OH)D indefinitely will improve tissue effect. That conclusion would require independent evidence demonstrating a beneficial dose-response relationship for the particular outcome.
Vitamin D physiology includes regulated activation, feedback, saturation and toxicity boundaries. Uncertainty about the exact translation from biomarker to function is therefore a reason for more disciplined interpretation, not a reason to assume that a higher laboratory number is always desirable.
The completed evidence rejects two opposite oversimplifications
The first oversimplification is that serum 25(OH)D directly measures how well vitamin D is functioning everywhere in the body. It does not. Several regulated biological layers separate circulating substrate from final tissue effect.
The second oversimplification is that those layers make the blood test meaningless. They do not. 25(OH)D remains a useful and established status biomarker. The correct scientific position lies between those extremes: the measurement is valid for the function it actually performs, while conclusions about downstream biological effect require additional evidence.
A unified model for interpreting vitamin D levels
The combined evidence can be represented as a sequence:
- Sun exposure, diet and supplementation influence vitamin D input.
- Hepatic metabolism contributes to the circulating 25(OH)D substrate pool.
- Vitamin D-binding protein, albumin and the free fraction shape transport in blood.
- Tissue delivery determines where substrate becomes available.
- CYP27B1-mediated activation produces 1,25(OH)₂D under endocrine or local regulation.
- CYP24A1 and related processes contribute to degradation and feedback control.
- Active vitamin D interacts with VDR and the cellular transcriptional machinery.
- Tissue-specific genomic and physiological context shapes the biological response.
- Functional and clinical outcomes occur downstream and may have additional determinants.
Routine serum 25(OH)D principally informs stage two. It may correlate with later stages because substrate availability is biologically relevant, but the correlation cannot be assumed to be complete, linear or identical for every endpoint.
How the two completed study pairs fit together
The first study pair establishes the measurement boundary. What Circulating Vitamin D Levels Measure: Biomarker Status Versus Biological Effect: Study Summary provides the concise route, while its Full Study establishes why 25(OH)D is a legitimate status marker without being a direct assay of tissue activity.
The second study pair explains the mechanisms of divergence. Why Measured Vitamin D Levels Can Diverge from Functional Biological Outcomes: Study Summary provides the concise route through binding, activation, degradation, receptor biology, tissue specificity and measurement variability, while its Full Study develops those mechanisms in depth.
Interpreting Vitamin D Levels in Physiological Context then places the same evidence into real-world interpretation by adding timing, season, population thresholds, exposure history and the need to distinguish plausible physiological mechanisms from explanations actually demonstrated in an individual.
The integrated conclusion
Circulating 25(OH)D is best understood as an upstream biomarker of vitamin D status within a regulated physiological system. Its value lies precisely in providing accessible information about the circulating substrate pool. Its limitation is that this pool is not synonymous with downstream biological effect.
Transport proteins can alter the composition of the circulating pool. Renal and extrarenal metabolism can alter active-hormone production. Catabolism can modify exposure. VDR competence and cellular regulatory architecture can alter response. Different tissues and endpoints can behave differently. Measurement variability, time and observational confounding can further influence the apparent relationship between the measured concentration and the outcome of interest.
The scientifically defensible interpretation therefore preserves both sides of the evidence. Vitamin D levels matter, but they must be asked the right question. A 25(OH)D result can inform vitamin D status. It cannot, by itself, quantify the complete biological effect of vitamin D throughout the body. Understanding that boundary allows laboratory measurement, mechanistic physiology and outcome evidence to complement one another without being collapsed into a single number.
Primary scientific sources
- Cashman KD et al. 25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and Its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population.
- Jones G. Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment.
- Bikle DD. Nonclassic Actions of Vitamin D.
- Chun RF et al. Vitamin D Binding Protein and the Biological Activity of Vitamin D.
- Pike JW et al. The Vitamin D Receptor: Contemporary Genomic Approaches Reveal New Basic and Translational Insights.
- Sempos CT et al. Analytical Considerations for the Biochemical Assessment of Vitamin D Status.
- Giustina A et al. Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.
Related reading
Active Vitamin D and Vitamin D Receptor Help Prevent High Glucose Induced Oxidative Stress of Renal Tubular Cells via AKT/UCP2 Signaling Pathway
JC-1 was evaluated by flow cytometry.
Original paper ↗Read more →Influence of vitamin D receptor polymorphisms on biochemical markers of mineral bone disorders in South African patients with chronic kidney disease
Therefore, the aim of this study was to examine the influence of vitamin D receptor (VDR) polymorphisms on secondary hyperparathyroidism and its association with vitamin D levels in black and white South African study participants.
Original paper ↗Read more →Interactions between Serum Vitamin D Levels and Vitamin D Receptor Gene FokI Polymorphisms for Renal Function in Patients with Type 2 Diabetes
We aimed to examine associations among serum 25-hydroxyvitamin D (25OHD) levels, 1,25-dihyroxyvitamin D (1,25OHD) levels, vitamin D receptor (VDR) polymorphisms, and renal function based on estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes.
Original paper ↗Read more →MiR-125b promotes migration and invasion by targeting the vitamin D receptor in renal cell carcinoma
To investigate the expression of miR-125b and vitamin D receptor (VDR) in renal cell carcinoma (RCC) and assess the biological function of miR-125b in RCC.
Original paper ↗Read more →Vitamin D receptor attenuate ischemia-reperfusion kidney injury via inhibiting ATF4
Activating transcription factor 4 (ATF4) is one of the key effectors of endoplasmic reticulum stress (ERS), ATF4/CHOP pathway-mediated ERS plays an important role in the progression of acute kidney disease (AKI).
Original paper ↗Read more →Vitamin D receptor gene polymorphisms in breast and renal cancer: Current state and future approaches
Here, we aimed to assess the correlation between the different alleles of VDR gene polymorphisms and renal cell cancer and breast cancer risks separately through a systematic review of the present literature.
Original paper ↗Read more →Vitamin D receptor polymorphisms and bone health after kidney transplantation
We investigated the relationship between the polymorphisms of the vitamin D receptor ( VDR ) gene and bone diseases occurring after kidney transplantation.
Original paper ↗Read more →Vitamin D receptor: a possible biomarker for sporadic parathyroid adenoma?
The aim of this study is to evaluate Vitamin D receptor expression in sporadic parathyroid adenoma.
Original paper ↗Read more →VDR-Related Alopecia and Unliganded Hair-Follicle Biology: Evidence Synthesis
Evidence synthesis of VDR mutation classes, alopecia and the evidence for unliganded VDR functions in hair-follicle biology.
Read more →Association Between VDR and CYP24A1 Polymorphisms, Atopic Dermatitis, and Biochemical Lipid and Vitamin D Profiles in Spanish Population: Case-Control Study
A total of 246 participants (143 patients with AD and 103 healthy controls) were enrolled in this study.
Original paper ↗Read more →Downregulation of serum vitamin D receptor level, serum 25-hydroxyvitamin D, and association of vitamin D receptor gene polymorphisms ApaI and TaqI with obesity in the Bangladeshi population
The purpose of our study was to investigate the association between two single-nucleotide polymorphisms (SNPs) (Apal, rs7975232, and Taql, rs731236) of the VDR gene and the risk of obesity in the Bangladeshi population.
Original paper ↗Read more →Plasma 25-Hydroxyvitamin D Level and VDR Gene Single Nucleotide Polymorphism rs2228570 Influence on COVID-19 Susceptibility among the Kazakh Ethnic Group: A Pilot Study
We compared the 25(OH)D plasma levels and concluded that the COVID-19-positive group values (25.17 ng/mL ± 16.65) were statistically lower (p = 0.0114) compared to the COVID-19-negative ones (35.58 ng/mL ± 20.67).
Original paper ↗Read more →Plasma 25-Hydroxyvitamin D Levels and VDR Gene Expression in Peripheral Blood Mononuclear Cells of Leukemia Patients and Healthy Subjects in Central Kazakhstan
A similar difference was observed in both younger (60 years old) participants, though there was no association between 25(OH)D concentration and age within the patient group.
Original paper ↗Read more →Relationship Between Vitamin D Receptor Gene BsmI Polymorphism and 25-Hydroxyvitamin D Total Levels in Slovak Postmenopausal Women with Reduced Bone Mineral Density
The aim of the study was to investigate the relationship between the VDR gene BsmI polymorphism and 25(OH)D levels in Slovak postmenopausal women.
Original paper ↗Read more →Upregulation of Placental Vitamin D Receptor Expression in Gestational Diabetes Is Not Directly Related to Vitamin D Concentration
This study aimed to examine the expression of the vitamin D receptor in the placenta of patients with gestational diabetes mellitus and healthy women.
Original paper ↗Read more →Variants in the VDR Gene May Influence 25(OH)D Levels in Type 1 Diabetes Mellitus in a Brazilian Population
This study aimed to evaluate the association of four variants in the VDR gene (rs7975232, rs1544410, rs731236, and rs2228570) with T1DM risk and vitamin D levels within a population from North Region, Brazil, as well as the influence of genomic ancestry on T1DM.
Original paper ↗Read more →Vitamin D Genetics Beyond Serum 25(OH)D: VDR rs2228570 (FokI) Polymorphism, Inflammation, and Quality of Life in Orthopedic Patients
This study investigated the rs2228570 (FokI) variant in relation to inflammatory, hematologic, and patient-reported outcomes in orthopedic patients.
Original paper ↗Read more →Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease
We aimed to investigate VDR binding in primary CD4+ cells from healthy volunteers.
Original paper ↗Read more →Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
Effect modification by serum 25-hydroxyvitamin D (25 [OH]D), the biomarker for vitamin D status in humans, has rarely been examined.
Original paper ↗Read more →Vitamin D Status, Bone Mineral Density, and VDR Gene Polymorphism in a Cohort of Belarusian Postmenopausal Women
The aim of this work was to reveal the effects of VDR gene ApaI rs7975232, BsmI rs1544410, TaqI rs731236, FokI rs2228570, and Cdx2 rs11568820 variants on bone mineral density (BMD), 25-hydroxyvitamin D level, and OP risk in Belarusian women.
Original paper ↗Read more →What Circulating Vitamin D Levels Measure: Biomarker Status Versus Biological Effect: Full Study
What does a vitamin D blood level actually measure?
Read more →Original sources
25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and Its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population
Cashman KD et al. 25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and Its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population.
Publication details
Cashman KD et al. 25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and Its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population.
Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment
Jones G. Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment.
Publication details
Jones G. Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment.
Nonclassic Actions of Vitamin D
Bikle DD. Nonclassic Actions of Vitamin D.
Publication details
Bikle DD. Nonclassic Actions of Vitamin D.
Vitamin D Binding Protein and the Biological Activity of Vitamin D
Chun RF et al. Vitamin D Binding Protein and the Biological Activity of Vitamin D.
Publication details
Chun RF et al. Vitamin D Binding Protein and the Biological Activity of Vitamin D.
The Vitamin D Receptor: Contemporary Genomic Approaches Reveal New Basic and Translational Insights
Pike JW et al. The Vitamin D Receptor: Contemporary Genomic Approaches Reveal New Basic and Translational Insights.
Publication details
Pike JW et al. The Vitamin D Receptor: Contemporary Genomic Approaches Reveal New Basic and Translational Insights.
Analytical Considerations for the Biochemical Assessment of Vitamin D Status
Sempos CT et al. Analytical Considerations for the Biochemical Assessment of Vitamin D Status.
Publication details
Sempos CT et al. Analytical Considerations for the Biochemical Assessment of Vitamin D Status.
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows
Giustina A et al. Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.
Publication details
Giustina A et al. Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.